TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04247282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 (1200 mg) will be administered intravenously on day 1 and 15 to patients enrolled in arm 1-3 (all three arms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 (1200 mg) will be administered intravenously on day 1 and 15 to patients enrolled in arm 1-3 (all three arms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 (1200 mg) will be administered intravenously on day 1 and 15 to patients enrolled in arm 1-3 (all three arms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N803
Description: N-803 (15 mcg/kg, subcutaneously) will be given on day 1 to patients enrolled in arm 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TriAd vaccine
Description: TriAd vaccine (5 x 10e(11) viral particles (VP); subcutaneous injection) will be given on day 1 to patients enrolled in arm 2 and arm 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TriAd vaccine
Description: TriAd vaccine (5 x 10e(11) viral particles (VP); subcutaneous injection) will be given on day 1 to patients enrolled in arm 2 and arm 3
Study: NCT03804710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Developmental moisturizing cream 1
Description: Participants will topically apply developmental moisturizing cream 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Developmental moisturizing cream 2
Description: Participants will topically apply developmental moisturizing cream 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard cleanser soap
Description: Participants will cleanse the entire face and both lower legs (between the knees and the ankles)with simple pure soap
Study: NCT03403868

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: conductance catheter
Description: pressure volume loops are assessed via a special catheter (Conductance catheter)
Study: NCT03353064

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivify
Description: A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivify
Description: A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
Study: NCT01292551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
Study: NCT02342886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HR (rifampicin plus isoniazid combination tablets)
Description: Oral
Study: NCT01064297

Intervention type: DRUG
Intervention: Lamotrigine monotherapy
Description: Lamotrigine monotherapy

Intervention type: DRUG
Intervention: Lamotrigine polytherapy including valproate
Description: Lamotrigine polytherapy including valproate

Intervention type: DRUG
Intervention: Lamotrigine polytherapy without valproate
Description: Lamotrigine polytherapy without valproate
Study: NCT00045305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Antimetabolite

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photopheresis
Description: Psoralens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycofenolate mofetil
Description: an antibiotic with immunosuppressamt properties isolated from Penicillium spp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Purine analogue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow
Description: Unmanipulated allogeneic bone marrow

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell
Description: G-CSF mobilized peripheral blood stem cell

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: a total of 600 cGy given in 3 200 cGy fractionated doses
Study: NCT00361439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone
Description: 2 puffs in each nostril once daily of nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs in each nostril once daily of nasal spray
Study: NCT01426971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBUPROFEN + CAFFEINE
Description: Pharmaceutical form: capsule Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBUPROFEN
Description: Pharmaceutical form: capsule Route of administration: oral
Study: NCT02259738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Urinary Kallidinogenase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuxuening injection
Study: NCT04370925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical colectomy
Description: Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical colectomy
Description: Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC(simultaneously or within 2days after resection) with mitomycin c (30 mg/m2) at 43°C for 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy
Description: Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable.
Study: NCT00140205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-metHuLeptin
Description: r-metreleptin was given in 3 different dose in fed and fasting states
Study: NCT01353781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
Study: NCT03427684

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-fractionated radiotherapy
Description: Hypo-fractionated radiotherapy with fraction \>2Gy .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 80mg/m2/day, orally intake on radiotherapy days.
Study: NCT03859882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep deprivation
Description: 40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
Study: NCT04859634

Intervention type: DEVICE
Intervention: Taking an ultra-widefield fundus image
Description: The participant only needs to take an ultra-widefield fundus image as usual.

Intervention type: DEVICE
Intervention: Taking an ultra-widefield fundus image
Description: The participant only needs to take an ultra-widefield fundus image as usual.

Intervention type: DEVICE
Intervention: Taking an ultra-widefield fundus image
Description: The participant only needs to take an ultra-widefield fundus image as usual.

Intervention type: DEVICE
Intervention: Taking an ultra-widefield fundus image
Description: The participant only needs to take an ultra-widefield fundus image as usual.

Intervention type: DEVICE
Intervention: Taking an ultra-widefield fundus image
Description: The participant only needs to take an ultra-widefield fundus image as usual.

Intervention type: DEVICE
Intervention: Taking an ultra-widefield fundus image
Description: The participant only needs to take an ultra-widefield fundus image as usual.

Intervention type: DEVICE
Intervention: Taking an ultra-widefield fundus image
Description: The participant only needs to take an ultra-widefield fundus image as usual.
Study: NCT04126408

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore
Description: The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore
Description: The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
Study: NCT00770926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Well, Be Well
Description: Lifestyle change program using personal contact and telephone counseling
Study: NCT02836223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interdental cleaning device
Description: Water Flosser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Tooth brush
Description: Control

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual Tooth brush
Description: Control
Study: NCT00168038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Intravenous (Human)
Description: A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
Study: NCT01274052

Intervention type: OTHER
Intervention: Meal test
Description: Liquid meal test

Intervention type: OTHER
Intervention: Meal test
Description: Liquid meal test
Study: NCT01938248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age \> 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 81 mg once daily
Study: NCT03872479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDIT-101
Description: Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDIT-101
Description: Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDIT-101
Description: Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDIT-101
Description: Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDIT-101
Description: Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.
Study: NCT04841941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G4 Multifocal soft contact lens with a 54% water content for presbyopia
Description: The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer.
Study: NCT01602406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJM716
Description: LJM716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab
Study: NCT04132843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate Dimeglumine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02432989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Light-moderate exercise on a stationary bike and leisurely walks.
Study: NCT00295022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Over-encapsulated tablet~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: * Pharmaceutical form: Over-encapsulated tablet~* Concentration: 10 mg~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: * Pharmaceutical form: Over-encapsulated tablet~* Concentration: 5 mg~* Route of administration: Oral use
Study: NCT02335190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory block
Description: Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT02475252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysteroscopy on a training model
Description: Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopy on a training model
Description: Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
Study: NCT03732352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo fludeoxyglucose F-18 PET scan
Study: NCT03773172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI6012
Description: MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will mimic the active treatment.
Study: NCT03005327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: Mavorixafor will be provided as either 25 mg or 100 mg capsules.
Study: NCT03010150

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Provide blood samples

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05748847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrastromal corneal ring segment implantation (Pocket)
Description: Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted pocket creation.~The device creates an intrastromal corneal pocket of 8-mm diameter and a depth of nearly 80% of the corneal thickness at the thinnest location with a superior tunnel incision at 90° of 5-mm width.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrastromal corneal ring segment implantation (Tunnel)
Description: Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted tunnel creation.~The device creates an intrastromal tunnel with a depth of nearly 80% of the corneal thickness at the site of implantation. The tunnel inner and outer diameters are at 5 and 6 mm from the corneal center, respectively with the incision located at the steepest keratometry axis.
Study: NCT04687072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous injection with efgartigimod PH20 SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: Subcutaneous injection with placebo PH20 SC
Study: NCT01604928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03158142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 1% Oph Soln
Description: Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
Study: NCT04120220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Cream
Description: Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with heavy cream.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil
Description: Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with soybean oil.
Study: NCT04352374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device guided breathing
Description: The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
Study: NCT01609660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: 100mg daily for seven days prior to surgery
Study: NCT03811379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity